
    
      This phase IIIb/IV trial involves patients with mild to moderate Alzheimer's Disease in
      Europe, Canada and Latin America and is designed as a prospective, randomized, double-blind,
      active-controlled, parallel-group, multicenter, double-dummy trial.

      The study endpoint is after 24 weeks. In total, five visits are scheduled in this trial and a
      follow-up phone call is performed 4 weeks after Visit 5 (Week 24).

      The first visit (Screening Visit, Visit 1) identifies participants who are eligible for and
      interested in this trial.Efficacy and safety parameters are assessed at the Baseline Visit
      (Visit 2), in Week 6-7 (Visit 3), Week 14-15 (Visit 4) and Week 24 (Visit 5).
    
  